Helus Pharma Inc. Common Stock
HELP
70 hedge funds and large institutions have $3.45M invested in Helus Pharma Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
15% more funds holding
Funds holding: 61 → 70 (+9)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
3.67% less ownership
Funds ownership: 10.13% → 6.46% (-3.7%)
58% less capital invested
Capital invested by funds: $8.22M → $3.45M (-$4.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$112K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$104K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$53.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$24.9K |
| 5 |
VF
Virtu Financial
New York
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.2M |
| 2 |
BlackRock
New York
|
-$362K |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$145K |
| 4 |
EL
EMFO LLC
Weston,
Florida
|
-$28.2K |
| 5 |
WLPWM
Walled Lake Planning & Wealth Management
Winnetka,
Illinois
|
-$28K |
HELP Hedge Fund Activity: Q4 2022 in Review
70 of the 6,240 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q4 2022, worth a combined $3.45M — down 58% from $8.22M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new HELP positions and 6 closed out — a net gain of 11 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was Belpointe Asset Management, opening a new position worth an estimated $112K. The largest seller was OrbiMed, cutting an estimated $2.2M.
- 70 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q4 2022, up from 61 in Q3 2022.
- Funds reported $3.45M of Helus Pharma Inc. Common Stock stock for Q4 2022, down 58% quarter-over-quarter.
- 17 funds opened new Helus Pharma Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of +11 holders.
- The largest Helus Pharma Inc. Common Stock buyer in Q4 2022 was Belpointe Asset Management, an estimated $112K added.
- The largest Helus Pharma Inc. Common Stock seller in Q4 2022 was OrbiMed, an estimated $2.2M sold.
Based on aggregated 13F filings for Q4 2022.